Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Non-Current Assets: 2023-2025

Historic Non-Current Assets for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $58.0 million.

  • Monte Rosa Therapeutics' Non-Current Assets fell 9.16% to $58.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.0 million, marking a year-over-year decrease of 9.16%. This contributed to the annual value of $61.3 million for FY2024, which is 9.25% down from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Non-Current Assets stood at $58.0 million, which was down 3.49% from $60.1 million recorded in Q2 2025.
  • Over the past 5 years, Monte Rosa Therapeutics' Non-Current Assets peaked at $70.5 million during Q2 2023, and registered a low of $58.0 million during Q3 2025.
  • For the 3-year period, Monte Rosa Therapeutics' Non-Current Assets averaged around $64.9 million, with its median value being $66.2 million (2024).
  • Data for Monte Rosa Therapeutics' Non-Current Assets shows a maximum YoY fell of 10.03% (in 2025) over the last 5 years.
  • Over the past 3 years, Monte Rosa Therapeutics' Non-Current Assets (Quarterly) stood at $67.5 million in 2023, then dropped by 9.25% to $61.3 million in 2024, then fell by 9.16% to $58.0 million in 2025.
  • Its Non-Current Assets was $58.0 million in Q3 2025, compared to $60.1 million in Q2 2025 and $60.9 million in Q1 2025.